15-Deoxy-Delta(12),(14)-prostaglandin J(2) and troglitazone regulation of the release of phospholipid metabolites, inflammatory cytokines and proteases from human gestational tissues

Lappas, M., Permezel, M. and Rice, G. E. (2006) 15-Deoxy-Delta(12),(14)-prostaglandin J(2) and troglitazone regulation of the release of phospholipid metabolites, inflammatory cytokines and proteases from human gestational tissues. Placenta, 27 11-12: 1060-1072. doi:10.1016/j.placenta.2005.11.009


Author Lappas, M.
Permezel, M.
Rice, G. E.
Title 15-Deoxy-Delta(12),(14)-prostaglandin J(2) and troglitazone regulation of the release of phospholipid metabolites, inflammatory cytokines and proteases from human gestational tissues
Formatted title
15-Deoxy-Δ12,14-Prostaglandin J2 and Troglitazone Regulation of the Release of Phospholipid Metabolites, Inflammatory Cytokines and Proteases from Human Gestational Tissues
Journal name Placenta   Check publisher's open access policy
ISSN 0143-4004
1532-3102
Publication date 2006-11
Sub-type Article (original research)
DOI 10.1016/j.placenta.2005.11.009
Volume 27
Issue 11-12
Start page 1060
End page 1072
Total pages 13
Place of publication Oxford, United Kindgom
Publisher Elsevier
Language eng
Formatted abstract
Phospholipid-derived mediators, inflammatory cytokines and extracellular matrix remodelling enzymes are all involved in the initiation of human labour and delivery. We have previously demonstrated that natural and synthetic PPAR-γ ligands regulate LPS-stimulated pro-inflammatory cytokine release from human gestational tissues, however, the effect of these ligands on the basal and/or LPS-induced expression of prostaglandins and proteases is not known. Therefore, the aim of this study was to determine the effects of 15d-PGJ2 and troglitazone on the expression of basal and LPS-stimulated inflammatory mediators in human gestational tissues. Human placenta, amnion and choriodecidua (n = 5) were incubated in the presence or absence of 15 μM 15d-PGJ2 and 30 μM troglitazone under basal and LPS-stimulated (10 μg/ml) conditions. Treatment of placenta, amnion and choriodecidua with both 15d-PGJ2 and troglitazone decreased basal and LPS-stimulated IL-1β, IL-6, IL-10 and TNF-α release. Basal type II PLA2 release from placental tissues was also significantly decreased by 15d-PGJ2 and troglitazone. There was no effects of 15d-PGJ2 and troglitazone on cPLA2 protein expression. Both 15d-PGJ2 and troglitazone significantly decreased basal and LPS-stimulated PGE2 and PGF release from placenta and amnion. However, in choriodecidua, although 15d-PGJ2 decreased basal and/or LPS-stimulated PGE2 and PGF2α release, there was an increase in PGE2 and PGF release in the presence of troglitazone. 15d-PGJ2 and troglitazone inhibited MMP-9 release from human amnion. NF-κB DNA binding activity and NF-κB p65 protein expression was inhibited by treatment with 15d-PGJ2 in human amnion. There was no effect of 15d-PGJ2 or troglitazone on PPAR-γ protein, and GW9662 failed to alleviate 15d-PGJ2 and troglitazone inhibition of IL-6 and TNF-α release in placenta, amnion and choriodecidua. The data demonstrated in this study suggest that the 15d-PGJ2 and troglitazone exhibit anti-inflammatory properties in human gestational tissues via PPAR-γ independent actions.
Keyword Placenta
Fetal Membranes
Cytokines
Prostaglandins
Protease
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: UQ Centre for Clinical Research Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 39 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 45 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 15 Jul 2011, 13:33:53 EST by System User on behalf of UQ Centre for Clinical Research